Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 24 of the 24 sources its claims cite were checked for support.

What is CRISPR/Cas9?

Open access
Redman, Melody, King, Andrew, Watson, Caroline, King, David · 2016 · Archives of disease in childhood - Education & practice edition

Abstract

Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology causing a major upheaval in biomedical research. It makes it possible to correct errors in the genome and turn on or off genes in cells and organisms quickly, cheaply and with relative ease. It has a number of laboratory applications including rapid generation of cellular and animal models, functional genomic screens and live imaging of the cellular genome.1 It has already been demonstrated that it can be used to repair defective DNA in mice curing them of genetic disorders,2 and it has been reported that human embryos can be similarly modified.3 Other potential clinical applications include gene therapy, treating infectious diseases such as HIV and engineering autologous patient material to treat cancer and other diseases. In this review we will give an overview of CRISPR/Cas9 with an emphasis on how it may impact on the specialty of paediatrics. Although it is likely to have a significant effect on paediatrics through its impact in the laboratory, here we will concentrate on its potential clinical applications. We will also describe some of the difficulties and ethical controversies associated with this novel technology. CRISPR/Cas9 is a gene-editing technology which involves two essential components: a guide RNA to match a desired target gene, and Cas9 (CRISPR-associated protein 9)—an endonuclease which causes a double-stranded DNA break, allowing modifications to the genome (see figure 1). Figure 1 The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. They afford protection against invading viruses, when combined with a series of CRISPR-associated (Cas) proteins. Cas9, one of the associated proteins, is an endonuclease that cuts both strands of DNA. Cas9 is directed to its target by a section of RNA. This can be synthesised as a single strand called …

Overview

CoChat Summary

TL;DR

CRISPR/Cas9 is a gene-editing technology pairing a guide RNA with the Cas9 endonuclease to create targeted double-stranded DNA breaks, enabling genome correction or gene regulation. This narrative review outlines its potential paediatric clinical applications—correcting monogenic disorders, treating HIV, and engineering somatic cells ex vivo—while flagging delivery, off-target, and germline-ethics challenges.

Key findings

  • CRISPR/Cas9 requires two components: a guide RNA matching the target gene and Cas9, an endonuclease that causes a double-stranded DNA break; repair via homology-directed repair allows edits "as precise as a single base-pair," while non-homologous end joining typically yields random insertions/deletions.
  • Preclinical disease applications cited: correction of the most common CF mutation in intestinal organoids from two patients restored CFTR function; AAV-delivered CRISPR/Cas9 recovered dystrophin expression and partial muscle function in a DMD mouse model; BCL11A enhancer disruption induced fetal haemoglobin in mice and primary human erythroblast cells.
  • HIV: CRISPR/Cas9 targeting of the HIV-1 genome inactivated viral gene expression and replication in latently infectable cells without toxic effects, and cells could be immunised against HIV-1 infection.
  • Ex vivo engineering: CRISPR/Cas9 enabled knockout and knock-in editing in primary human CD4+ T-cells (including blocking PD-1 expression), and correction of the β-thalassaemia mutation in human induced pluripotent stem cells.

Methods

  • Design: narrative review article (not primary research), aimed at describing CRISPR/Cas9 and its potential impact on paediatrics, with emphasis on clinical applications and associated difficulties and ethical controversies.
  • Data: no original dataset; the review synthesises published preclinical and in vitro studies (e.g., Schwank et al on CF organoids, Tabebordbar et al on DMD mice, Canver et al on BCL11A, Hu et al on HIV-1, Schumann et al on T-cells, Xie et al on β-thalassaemia iPSCs).
  • Analysis: descriptive synthesis of cited literature; no formal quantitative analysis reported.

Limitations

  • Stated: delivery to the right cells in vivo remains a particular issue—AAV may be too small to transduce the Cas9 gene efficiently, and a smaller Cas9 has efficacy implications; other non-viral delivery systems need optimisation.
  • Stated: off-target effects elsewhere in the genome could cause long-term complications including malignancy; Cas9 concentration and expression duration matter, and long-term safety is unestablished.
  • Stated: germline/embryo editing is permanent with unclear long-term consequences, and ethical boundaries remain undetermined; the review notes its therapeutic examples are predominantly directed at somatic cells. Evident from the text: the clinical applications discussed are largely preclinical or in vitro, so bedside translation is not yet demonstrated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/archdischild-2016-310459

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. They afford protection against invading viruses, when combined with a series of CRISPR-associated (Cas) proteins. Cas9, one of the associated proteins, is an endonuclease that cuts both strands of DNA. Cas9 is directed to its target by a section of RNA. This can be synthesised as a single strand called a synthetic single guide RNA (sgRNA); the section of RNA which binds to the genomic DNA is 18–20 nucleotides. In order to cut, a specific sequence of DNA of between 2 and 5 nucleotides (the exact sequence depends upon the bacteria which produces the Cas9) must lie at the 3’ end of the guide RNA: this is called the protospacer adjacent motif (PAM). Repair after the DNA cut may occur via two pathways: non-homologous end joining, typically leading to a random insertion/deletion of DNA, or homology directed repair where a homologous piece of DNA is used as a repair template. It is the latter which allows precise genome editing: the homologous section of DNA with the required sequence change may be delivered with the Cas9 nuclease and sgRNA, theoretically allowing changes as precise as a single base-pair.
Figure 1 The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. They afford protection against invading viruses, when combined with a series of CRISPR-associated (Cas) proteins. Cas9, one of the associated proteins, is an endonuclease that cuts both strands of DNA. Cas9 is directed to its target by a section of RNA. This can be synthesised as a single strand called a synthetic single guide RNA (sgRNA); the section of RNA which binds to the genomic DNA is 18–20 nucleotides. In order to cut, a specific sequence of DNA of between 2 and 5 nucleotides (the exact sequence depends upon the bacteria which produces the Cas9) must lie at the 3’ end of the guide RNA: this is called the protospacer adjacent motif (PAM). Repair after the DNA cut may occur via two pathways: non-homologous end joining, typically leading to a random insertion/deletion of DNA, or homology directed repair where a homologous piece of DNA is used as a repair template. It is the latter which allows precise genome editing: the homologous section of DNA with the required sequence change may be delivered with the Cas9 nuclease and sgRNA, theoretically allowing changes as precise as a single base-pair.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 0 Not valid · 0 Not checked · 9 Own results and interpretations

16 more claims · 12 with their cited sources checked

Create a free account to see all 32 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 6
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Cited by

See all 325

Metadata

Authors
Redman, M., King, A., Watson, C., & King, D.
Affiliations
  • University of York (GB)
  • John Radcliffe Hospital (GB)
  • Churchill Hospital (GB)
  • Sheffield Children's Hospital (GB)
Corresponding author
King, David
Venue
Archives of disease in childhood - Education & practice edition
Publisher
BMJ
Published
2016-04-08
Volume
101
Issue
4
Pages
213-215
ISSN
  • 1743-0585 (ISSN-L)
  • 1743-0593
OpenAlex
W2339144537
Cited by
248
References
14
Citations by year
2026: 25 · 2025: 71 · 2024: 56 · 2023: 30 · 2022: 29 · 2021: 15 · 2020: 9 · 2019: 5 · 2018: 2 · 2017: 4 · 2016: 1
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Archives of Disease in Childhood Education & Practice (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Wellcome Trust (108785/Z/15/Z)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9, genome editing, guide RNA, Cas9 endonuclease, clinical application, gene therapy, genetic disorders, ethical controversies, HIV treatment, cancer immunotherapy
MeSH terms
Adolescent, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Pediatrics, Disease Management, Gene Silencing, Young Adult, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What is CRISPR/Cas9? https://app.cochat.ai/papers/10.1136/archdischild-2016-310459
The paper
Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR/Cas9? Archives of disease in childhood - Education & practice edition. https://doi.org/10.1136/archdischild-2016-310459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.